PFKFB3 and small cell lung carcinoma: Latest research demonstrates inhibiting glycolysis rate-limiting enzyme 6-phosphofructo-2-kinase (PFK2) effectively attenuate malignant phenotype including growth ability, stemness and metastasis potential in SCLC [34].